Evidence map›Paper›PMID 41613778›Full record

ArticleFrontiers in pharmacology2026

Failure patterns and clinical indications in early-stage follicular lymphoma: a study from the National Cancer Center in China.

Chang Xu, Shijie Yang, Yue Liu, Yunpeng Wu, Xin Liu, Qiu-Zi Zhong, Yong Yang, Tao Wu, Si-Ye Chen, Bo Chen and 13 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Chang Xu *Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shijie Yang *Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yue Liu *Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yunpeng WuDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xin LiuDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qiu-Zi ZhongDepartment of Radiation Oncology, Beijing Hospital, National Geriatric Medical Center, Beijing, China.
Yong YangDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Tao WuAffiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, Guizhou, China.
Si-Ye ChenDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bo ChenDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yong-Wen SongDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hui FangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jing JinDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yue-Ping LiuDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hao JingDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yuan TangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ning LiDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ning-Ning LuDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wen-Wen ZhangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shu-Lian WangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jingru ZhuDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shu-Nan QiDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ye-Xiong LiDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: The optimal management of early-stage follicular lymphoma (FL) remains an active research area, particularly in China. This retrospective cohort study examined long-term survival outcomes, recurrence patterns, and potential prognostic factors in patients with early-stage FL. Materials and Methods: We retrospectively analyzed 107 patients diagnosed with early-stage FL between 2000 and 2020 at the National Cancer Center in China. Treatment modalities included radiotherapy with or without chemoimmunotherapy or chemotherapy, chemoimmunotherapy or chemotherapy, and observation. Overall survival, progression-free survival, and lymphoma-specific survival were assessed using the Kaplan-Meier method and Cox regression models. We evaluated failure patterns, including locoregional and systemic failures, using cumulative incidence analysis with competing risks. Exploratory LASSO regression and machine learning-based approaches were applied to identify potential prognostic factors. Results: The median age was 53 years, and the median follow-up was 86 months. In this 20-year real-world cohort from the National Cancer Center of China (n = 107), long-term outcomes were favorable, with 5- and 10-year rates of 88.7% and 68.8% for OS, 93.3% and 89.9% for LSS, and 76.0% and 57.2% for PFS. No statistically significant differences in survival or cumulative failure were observed across initial management strategies, including radiotherapy with or without systemic therapy, systemic therapy alone, and observation. Recurrence occurred in 21 patients (19.6%), predominantly locoregional (14 locoregional only vs. 6 systemic only; 1 both). The 5- and 10-year cumulative incidences were 16.3% and 19.5% for overall failure, 14.5% and 16.2% for locoregional failure, and 3.1% and 4.8% for systemic failure. POD24 occurred in 6.5% of patients and was associated with inferior OS, although event numbers were limited. Low neutrophil-to-lymphocyte ratio (NLR <1.8) was associated with poorer survival in exploratory analyses. Conclusion: Patients with early-stage FL in this 20-year real-world Chinese cohort demonstrated an overall favorable long-term prognosis across diverse initial management strategies. No treatment modality showed a clear survival advantage in this limited-size cohort, while relapse was uncommon and more frequently locoregional than systemic. POD24 identified a small subset of patients with inferior survival, highlighting the need for individualized, risk-adapted management and long-term follow-up.

Indexed as

failurefollicular lymphomamachine learningradiotherapysurvival outcome

Identifiers

PMID41613778
PMCPMC12847288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.